Study Name: A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-103 in Participants Ages 12-35 with Recent Onset Stage 3 Type 1 Diabetes
Principal Investigator: Timothy P Foster, M.D.
What is CNP-103 Study in Type 1 Diabetes (T1D)??
This study is testing CNP-103, an investigational anitgen-specific immune tolerance therapy, for patients recently diagnosed with type 1 diabetes (T1D). The main goal of the trial is to evaluate if CNP-103 is safe and well-tolerated. Another goal is to determine if CNP-103 can help recently diagnosed patients retain some of their body’s own insulin-producing ability. Despite advances in insulin delivery and blood sugar monitoring, people with T1D still face significant health consequences related to the disease. Preserving pancreatic function and natural insulin production remains the optimal approach for managing T1D.
Who can participate?
- Participants who are between 12 and 35 years old
- Were diagnosed with type 1 diabetes in the past 6 months
What can I expect if I decide to participate?
Study participation lasts about 13 months and will include at least 10 visits at the study center. If you are eligible, you will be randomly chosen to receive either CNP-103 or a placebo (an inactive substance). There is a 2 in 3 chance of receiving CNP-103. Neither you nor your study doctor will know which one you receive. The test drug (or placebo) will be given through the vein in your arm (intravenously, IV). During the study duration, the study team will monitor your health through check-ups and medical tests.
Learn more about this study and see where else it’s being conducted.
Want to learn more?
Call (352) 294-5760 or email our Study Coordinators: